Saltar a casilla de búsquedaSaltar a navegaciónIr directamente al contenido principal

The therapeutic window after spinal cord injury can accommodate T cell-based vaccination and methylprednisolone in rats

  • Antonio Ibarra(corresponding author)
    ,
  • Ehud Hauben
    ,
  • Oleg Butovsky
    ,
  • Michal Schwartz
*Corresponding author for this work
  • Weizmann Institute of Science
    ,
  • CAMINA Project Research Center
Research Output:
Contribución a una revista
Artículo
Revisión por expertos

Publication Information

Tipo de resultado

Research Output:
Contribución a una revista
Artículo
Revisión por expertos

Idioma original

Inglés

Páginas desde-hasta (Número de páginas)

Páginas 2984-2990 (7 páginas)

Revista (Volumen, Número de Edición)

European Journal of Neuroscience (Volumen 19, Número 11)

Hitos de publicación

  • Publicada - 01/06/2004

Estado de publicación

Publicada - 01/06/2004

ISSN

0953-816X

Publication IDs

  • Scopus: 3042662126
  • PubMed: 15182305

Abstract

Immune system activity has traditionally been considered harmful for recovery after spinal cord injury (SCI). Recent evidence suggests, however, that immune activity - and specifically autoimmune activity - is evoked by the insult, is beneficial if properly regulated and is amenable to boosting. Thus, for example, vaccination with an altered peptide ligand derived from myelin basic protein reduces the progressive degeneration of neurons that escaped the initial insult, thereby promoting recovery after SCI. As the steroid drug methylprednisolone (MP) is currently the only treatment available for patients with SCI, our purpose in the present study was to examine the mutual compatibility of the two treatments within the post-traumatic therapeutic window. We show, using rats of two different strains, that if MP is injected concomitantly with the therapeutic vaccination, the beneficial effect of the vaccination is diminished. However, if MP is given immediately after the insult and the vaccination 48 h later, MP does not detract from the beneficial effect of the vaccination. These results demonstrate that the therapeutic window after SCI can accommodate immediate administration of MP plus a delayed therapeutic vaccination.